Waldencast plc Agrees to Sell Obagi Medical Segment for 460 Million Dollars
Waldencast plc (NASDAQ: WALD) announced a definitive agreement to sell its Obagi Medical division on June 1, 2026. The dermatological skincare and aesthetics business will be acquired by the private equity firm Bridgepoint. The total transaction value reaches up to $460 million. Following this announcement, the company’s shares surged by over 50% in standard trading sessions. Public investors reacted with immense enthusiasm to the sudden reduction in corporate leverage. The corporate restructuring represents a major turning point for the consumer goods entity.
Financial Architecture of the Asset Divestiture
The multi-layered deal structure provides substantial upfront liquidity for the parent organization. The total package includes $366 million in cash delivered at closing. Additionally, the transaction features $30 million in principal vendor notes. These notes carry a maturity timeline of seven and a half years. The agreement also provides up to $64 million in performance-based earnout milestones. These contingent payouts depend heavily on revenue metrics throughout 2026 and 2027. Furthermore, the contract establishes a reverse termination fee of $16 million to protect the seller. This component reduces execution risks if the buyer fails to finalize the transaction.
Balance Sheet De-leveraging and Debt Resolution
The primary motivation behind this asset sale is the complete optimization of the corporate capital structure. Consequently, management plans to deploy the incoming capital directly toward debt resolution. The firm expects to fully repay its $178 million senior secured term loan facility with Lumina Capital Management. Prior to this corporate development, heavy debt loads had depressed the equity value. The company previously carried total liabilities that hindered operational flexibility. Therefore, removing this debt layer eliminates major interest expense headwinds. The divestiture drastically improves the firm’s current ratio and short-term liquidity metrics.
Sharpening Strategic Focus on Milk Makeup
The platform will operate purely as a single-brand vehicle centered on cosmetics. In addition, resources will be heavily redirected toward accelerating the international growth of Milk Makeup. This cosmetics division remains highly popular within the clean beauty ecosystem. In fiscal year 2025, Milk Makeup generated $110.4 million in net revenue. The brand also delivered a robust $15.2 million in adjusted EBITDA. On the other hand, international growth patterns historically struggled to offset localized cooling in domestic consumer markets. Management believes a concentrated strategy will help unlock the true underlying valuation of this high-growth asset.
Executive Leadership Reorganization and Governance Transitions
The massive transaction results in a structural shift across the executive governance team. Founders Michel Brousset and Hind Sebti will exit the public firm. Subsequently, they will transition to lead Obagi Medical independently in partnership with Bridgepoint. Felipe Dutra will take over the public company as Executive Chairman. He will directly oversee the corporate transition period. Meanwhile, brand co-founder Mazdack Rassi will continue leading daily operations for the cosmetics business. This structural separation allows both unique business units to pursue tailored operational roadmaps under distinct ownership models.
Long-Term Market Outlook and Investment Considerations
Public equity managers are closely examining the revised financial footprint of the business. Before the announcement, the stock suffered a 54% decline over the trailing twelve months. In contrast, the recent price pop demonstrates how quickly the market rewards aggressive corporate de-leveraging. The firm’s price-to-sales ratio was hovering at a modest 0.78 prior to the rally. This metric suggested significant historical undervaluation relative to legacy beauty peers. As a result, the streamlined corporate structure may attract institutional buyers focused on high-margin cosmetics platforms. The transaction is projected to officially close during the third quarter of 2026.
Strategic Investment Summary
- Transaction Valuation: Waldencast plc (NASDAQ: WALD) is divesting its Obagi Medical unit to Bridgepoint for an enterprise value of up to $460 million.
- Payment Components: The deal features a guaranteed $366 million cash payout at closing, alongside $30 million in vendor notes and up to $64 million in revenue-based earnouts.
- Debt Eradication: The incoming proceeds will completely wipe out the company’s outstanding $178 million senior secured term loan facility.
- Corporate Focus: Post-transaction operations will center entirely on expanding and scaling the high-growth Milk Makeup cosmetics brand globally.
- Leadership Handover: Corporate founders Michel Brousset and Hind Sebti are stepping down to manage Obagi Medical under private equity ownership.
- Brand Financial Strength: Milk Makeup remains highly profitable independently, generating $110.4 million in net revenue and $15.2 million in adjusted EBITDA during 2025.
- Timeline to Close: The asset divestiture has receivedę unanimous approval from disinterested board members and is set to finalize in the third quarter of 2026.
Find out more about the latest portfolio restructuring and financial metrics at the Waldencast investor portal.
